DRIONasdaq

DarioHealth Corp.

Healthcare·Neurology·New York, NY, United States
NeurologyMetabolicPainMusculoskeletal

DarioHealth Corp. (DRIO): 4 pipeline candidates · ~11 mo cash runway. Updated within the last hour.

6.8/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway3.1

11.1 months

Financial Health10.0

0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for DarioHealth Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$52.2M

Cash

$15.0M

Quarterly Burn

$6.0M

Runway

11.1 mo

Revenue

$5.6M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2027
Today~12 mo out
Catalyst within runway

Pipeline (4 candidates)

·CEO: Mr. Erez Raphael

Frequently asked questions

How many drug candidates are in DarioHealth Corp.'s pipeline?

DarioHealth Corp. (DRIO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is DarioHealth Corp.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, DarioHealth Corp. has approximately 11.1 months of cash runway.

What is DarioHealth Corp.'s market capitalization?

DarioHealth Corp.'s market capitalization is approximately $52.2M.

Who is the CEO of DarioHealth Corp.?

Mr. Erez Raphael is the chief executive officer of DarioHealth Corp. (DRIO).

Get the full picture on DarioHealth Corp.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.